• EN

    • -+ 0.00%
    -+ 0.00%
    -+ 0.00%

    What Revolution Medicines (RVMD)'s RASONQUE Pancreatic Cancer Focus Means For Shareholders

    Simply Wall St·08/26/2026 21:24:37
    Listen to the news
    • Earlier this year, Revolution Medicines held a special call to discuss RASONQUE™ (daraxonrasib), described as the first broad RAS‑targeted medicine for metastatic pancreatic cancer and other company updates.
    • This focus on a broad RAS‑targeted therapy in a hard‑to‑treat tumor type highlights how Revolution Medicines is trying to translate its RAS(ON) science into real‑world clinical impact.
    • We’ll now examine how this RASONQUE™ pancreatic cancer update fits into Revolution Medicines’ broader RAS(ON) franchise and investment narrative.

    Uncover the next big thing with 22 elite penny stocks that balance risk and reward.

    Revolution Medicines Investment Narrative Recap

    To own Revolution Medicines, you need to believe its RAS(ON) platform can turn strong pancreatic cancer data into approved drugs and, eventually, meaningful revenue. The recent RASONQUE™ call reinforces daraxonrasib’s central role, but the core near term catalyst remains FDA review of the daraxonrasib NDA in metastatic pancreatic cancer. The biggest current risk is the company’s heavy cash burn relative to zero revenue, and this update does not materially change that imbalance.

    Among recent announcements, the FDA’s acceptance of the daraxonrasib NDA for previously treated metastatic pancreatic ductal adenocarcinoma is most relevant here. It formally links the RASolute 302 survival data to a potential first commercial product and sets a clearer regulatory timeline. How that review process unfolds, in parallel with Revolution’s expanding late stage trial program and rising operating expenses, will frame both the upside from RAS(ON) approvals and the pressure from continued losses.

    Yet behind the excitement around daraxonrasib, the scale and timing of future dilution and funding needs are things investors should really understand before...

    Read the full narrative on Revolution Medicines (it's free!)

    Revolution Medicines' narrative projects $3.4 billion revenue and $215.8 million earnings by 2029. This requires earnings to increase by about $2.0 billion from -$1.8 billion today.

    Uncover how Revolution Medicines' forecasts yield a $221.90 fair value, a 3% upside to its current price.

    Exploring Other Perspectives

    RVMD 1-Year Stock Price Chart
    RVMD 1-Year Stock Price Chart

    Before this pancreatic cancer update, the most cautious analysts were modeling about US$838.8 million of revenue and US$158.7 million of earnings by 2029, so if you lean more conservative, this new data could either soften those concerns or reinforce them, depending on how you weigh the RAS(ON) opportunity against the risk that colorectal and other complex settings prove slower to contribute.

    Explore 5 other fair value estimates on Revolution Medicines - why the stock might be worth over 3x more than the current price!

    Decide For Yourself

    Don't just follow the ticker - dig into the data and build a conviction that's truly your own.

    Ready To Venture Into Other Investment Styles?

    Markets shift fast. These stocks won't stay hidden for long. Get the list while it matters:

    This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.